| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
VSTM
Verastem
|
Aug 07, 2026 | BUY |
Strong Buy
+126.2% avg upside
24 analysts
|
$18.00
166.97% Upside
|
+0.0% | · |
|
CGON
CG Oncology, Inc.
|
Aug 07, 2026 | BUY |
Strong Buy
+14.4% avg upside
17 analysts
|
$100.00
33.13% Upside
|
+0.0% | · |
|
FHTX
Foghorn Therapeutics
|
Aug 07, 2026 | BUY |
Strong Buy
+96.5% avg upside
17 analysts
|
$13.00
114.24% Upside
|
· | · |
|
ZNTL
Zentalis Pharmaceuticals
|
Aug 07, 2026 | BUY |
Buy
+231.4% avg upside
18 analysts
|
$10.00
137.07% Upside
|
· | · |
|
SRRK
Scholar Rock Holding
|
Aug 07, 2026 | BUY |
Strong Buy
+8.3% avg upside
23 analysts
|
$65.00
22.92% Upside
|
· | · |
|
RLMD
Relmada Therapeutics
|
Aug 07, 2026 | BUY |
Buy
+180.0% avg upside
15 analysts
|
$12.00
142.84% Upside
|
· | · |
|
CRBP
Corbus Pharmaceuticals
|
Aug 07, 2026 | BUY |
Strong Buy
+253.3% avg upside
20 analysts
|
$35.00
244.14% Upside
|
+0.0% | · |
|
IMRX
Immuneering
|
Aug 06, 2026 | BUY |
Strong Buy
+300.2% avg upside
12 analysts
|
$14.00
210.52% Upside
|
+1.1% | · |
|
SNDX
Syndax Pharmaceuticals
|
Aug 05, 2026 | BUY |
Strong Buy
+74.8% avg upside
27 analysts
|
$38.00
86.37% Upside
|
+2.4% | · |
|
KROS
Keros Therapeutics
|
Aug 04, 2026 | BUY |
Strong Buy
+116.9% avg upside
21 analysts
|
$20.00
79.38% Upside
|
-2.5% | · |
|
IBRX
ImmunityBio
|
Aug 04, 2026 | BUY |
Strong Buy
+47.0% avg upside
12 analysts
|
$15.00
96.25% Upside
|
+9.9% | · |
|
CADL
Candel Therapeutics
|
Jul 29, 2026 | BUY |
Strong Buy
+70.9% avg upside
11 analysts
|
$23.00
117.18% Upside
|
+12.6% | · |
|
MNPR
Monopar Therapeutics Inc
|
Jul 22, 2026 | BUY |
Strong Buy
-15.6% avg upside
18 analysts
|
$125.00
4.94% Upside
|
+5.4% | · |
|
ERAS
Erasca
|
Jul 14, 2026 | BUY |
Strong Buy
+8.6% avg upside
14 analysts
|
$20.00
8.66% Upside
|
-5.6% | · |
|
IMNM
Immunome
|
Jul 09, 2026 | BUY |
Strong Buy
+35.2% avg upside
16 analysts
|
$40.00
59.80% Upside
|
+3.6% | · |
|
TCRX
TScan Therapeutics
|
Jun 23, 2026 | BUY |
Strong Buy
+967.6% avg upside
12 analysts
|
$7.00
779.19% Upside
|
-13.6% | · |
|
ENGN
enGene Holdings
|
Jun 16, 2026 | BUY |
Buy
+455.5% avg upside
13 analysts
|
$4.00
122.16% Upside
|
+2.9% | · |
|
STRO
Sutro Biopharma
|
May 26, 2026 | BUY |
Strong Buy
+56.2% avg upside
21 analysts
|
$50.00
97.00% Upside
|
-7.3% | · |
|
AURA
Aura Biosciences Inc
|
May 26, 2026 | BUY |
Strong Buy
+164.8% avg upside
9 analysts
|
$24.00
200.31% Upside
|
-5.7% | · |
|
NBP
NovaBridge Biosciences
|
May 26, 2026 | BUY |
Strong Buy
+1108.3% avg upside
14 analysts
|
$9.00
414.30% Upside
|
-5.9% | · |
|
TARA
Protara Therapeutics
|
May 20, 2026 | BUY |
Strong Buy
+1160.4% avg upside
21 analysts
|
$27.00
555.42% Upside
|
-14.1% | · |
|
HOWL
Werewolf Therapeutics
|
Dec 19, 2025 | BUY |
Strong Buy
+1637.6% avg upside
8 analysts
|
$4.00
907.36% Upside
|
-41.5% | · |
|
IMA
ImageneBio
|
Nov 11, 2024 | BUY |
Buy
+194.9% avg upside
12 analysts
|
$4.00
29.63% Downside
|
-72.9% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.